Abstract | AIM: MATERIALS AND METHODS: QL was studied in 30 IHD patients with CHF of NYHA class II-IV, ejection fraction > 45%; 40 IHD patients without CHF and 30 healthy subjects. CHF patients were treated for 30 days with oral mildronate (250 mg 4 times a day). QL was assessed according to the method SF-36 Health Status Survey. RESULTS: QL in CHF patients is much lower than that of the controls. Objective severity of the disease and subjective satisfaction with life do not always coincide. Mildronate in a dose 1 g/day per os may be beneficial for LQ of CHF patients. CONCLUSION: It is thought desirable to include QL in analysis of efficiency of managing patients with CHF. SF-36 is a tool able to follow up changes in QL of CHF patients within a short-term treatment period.
|
Authors | A O Nedoshivin, N N Petrova, A E Kutuzova, N B Perepech |
Journal | Terapevticheskii arkhiv
(Ter Arkh)
Vol. 71
Issue 8
Pg. 10-2
( 1999)
ISSN: 0040-3660 [Print] Russia (Federation) |
Vernacular Title | Kachestvo zhizni bol'nykh s khronicheskoĭ serdechnoĭ nedostatochnost'iu. Effekt lecheniia mildronatom. |
PMID | 10515026
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Cardiovascular Agents
- Methylhydrazines
- 3-(2,2,2-trimethylhydrazine)propionate
|
Topics |
- Administration, Oral
- Adult
- Cardiovascular Agents
(administration & dosage, therapeutic use)
- Chronic Disease
- Female
- Heart Failure
(drug therapy, physiopathology, psychology)
- Humans
- Male
- Methylhydrazines
(administration & dosage, therapeutic use)
- Middle Aged
- Myocardial Ischemia
(drug therapy, physiopathology, psychology)
- Patient Satisfaction
- Quality of Life
- Stroke Volume
(drug effects)
- Treatment Outcome
|